S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Prothena Stock Forecast, Price & News

+0.23 (+0.84%)
(As of 06/24/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
709,800 shs
Average Volume
446,364 shs
Market Capitalization
$1.30 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

PRTA Stock Forecast (MarketRank)

Overall MarketRank

2.66 out of 5 stars

Medical Sector

71st out of 1,411 stocks

Pharmaceutical Preparations Industry

23rd out of 672 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.0 5 -4 -3 -2 -1 -
Prothena logo

About Prothena (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
$66.97 million
Pretax Margin


Sales & Book Value

Annual Sales
$200.58 million
Cash Flow
$1.58 per share
Book Value
$10.00 per share


Free Float
Market Cap
$1.30 billion

Prothena Frequently Asked Questions

Should I buy or sell Prothena stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prothena stock.
View analyst ratings for Prothena
or view top-rated stocks.

What is Prothena's stock price forecast for 2022?

7 analysts have issued 1 year price objectives for Prothena's stock. Their PRTA stock forecasts range from $14.00 to $103.00. On average, they expect Prothena's share price to reach $71.00 in the next year. This suggests a possible upside of 155.7% from the stock's current price.
View analysts' price targets for Prothena
or view top-rated stocks among Wall Street analysts.

How has Prothena's stock price performed in 2022?

Prothena's stock was trading at $49.40 at the start of the year. Since then, PRTA shares have decreased by 43.8% and is now trading at $27.77.
View the best growth stocks for 2022 here

When is Prothena's next earnings date?

Prothena is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Prothena

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.07. The biotechnology company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.23 million. Prothena had a net margin of 33.45% and a trailing twelve-month return on equity of 16.02%.
View Prothena's earnings history

Who are Prothena's key executives?

Prothena's management team includes the following people:
  • Dr. Gene G. Kinney Ph.D., Pres, CEO & Director (Age 53, Pay $1.02M)
  • Mr. Tran B. Nguyen M.B.A., CFO & Chief Strategy Officer (Age 48, Pay $745.35k)
  • Mr. Brandon S. Smith, Chief Operating Officer (Age 47, Pay $648.34k)
  • Ms. Carol D. Karp, Chief Regulatory Officer (Age 69, Pay $679.3k) (LinkedIn Profile)
  • Dr. Hideki Garren M.D., Ph.D., Chief Medical Officer (Age 57, Pay $859.64k)
  • Ms. Karin L. Walker C.P.A., CPA, Chief Accounting Officer & Controller (Age 59) (LinkedIn Profile)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 49)
  • Ms. Jennifer Zibuda, Director of Investor Relations & Communication
  • Mr. Michael J. Malecek, Chief Legal Officer (Age 56) (LinkedIn Profile)
  • Dr. Radhika Tripuraneni M.P.H., M.D., Chief Devel. Officer (Age 42)

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

Who are Prothena's major shareholders?

Prothena's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.26%), State Street Corp (5.06%), First Light Asset Management LLC (3.93%), Palo Alto Investors LP (3.59%), Dimensional Fund Advisors LP (3.22%) and Vanguard Group Inc. (1.87%). Company insiders that own Prothena stock include Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Karin L Walker, Michael J Malecek, Richard T Collier, Shane Cooke and Wagner M Zago.
View institutional ownership trends for Prothena

Which institutional investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Citigroup Inc., Healthcare of Ontario Pension Plan Trust Fund, TD Asset Management Inc., Massachusetts Financial Services Co. MA, First Trust Advisors LP, Vanguard Group Inc., and Federated Hermes Inc.. Company insiders that have sold Prothena company stock in the last two years include Carol D Karp, Christopher S Henney, Dennis J Selkoe, Karin L Walker, Michael J Malecek, Richard T Collier, Shane Cooke, and Wagner M Zago.
View insider buying and selling activity for Prothena
or view top insider-selling stocks.

Which institutional investors are buying Prothena stock?

PRTA stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Paradigm Biocapital Advisors LP, First Light Asset Management LLC, Sessa Capital IM L.P., Renaissance Technologies LLC, Prosight Management LP, Capital Fund Management S.A., and Mariner LLC.
View insider buying and selling activity for Prothena
or or view top insider-buying stocks.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $27.77.

How much money does Prothena make?

Prothena (NASDAQ:PRTA) has a market capitalization of $1.30 billion and generates $200.58 million in revenue each year. The biotechnology company earns $66.97 million in net income (profit) each year or $1.22 on an earnings per share basis.

How many employees does Prothena have?

Prothena employs 82 workers across the globe.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The official website for Prothena is www.prothena.com. The biotechnology company can be reached via phone at (531) 236-2500, via email at [email protected], or via fax at 353-1902-3510.

This page (NASDAQ:PRTA) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.